Zobrazeno 21 - 30
of 126
pro vyhledávání: '"Viola W. Zhu"'
Autor:
Egbert F Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M Tho, Xiuning Le, Julien Mazieres, How S Hin, Masahire Morise, Viola W Zhu, Daniel Tan, Kristina H Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl M Schumacher, Niki Karachaliou, Yi-Long Wu
Publikováno v:
Future Oncology. 18:1039-1054
MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line osimertinib. Combining osimertinib with a MET inhibit
Autor:
Sai-Hong Ignatius Ou, Xingxiang Xu, Yuan Chen, Chuan Li, Ying Cheng, Ziping Wang, Changan Sun, Kai Wang, Jianhua Chen, Qiong Wu, Zhehai Wang, R. Guo, Te Chun Hsia, Zhuang Yu, Jian Fang, Shaoshui Chen, Haihua Yang, Yong Song, Chin-Chou Wang, Xiaorong Dong, Jianxing He, Her-Shyong Shiah, Ping Wang, Cheng-Ta Yang, Hongying Wei, Yuping Sun, Viola W. Zhu, Jianhua Shi, Guojun Zhang, Wu Chou Su, Jifeng Feng, Jianying Zhou, Jiuwei Cui, Nong Yang, Shun Lu, Yanping Hu, Qiming Wang, Hongming Pan, Chao-Hua Chiu, Gee-Chen Chang, You Lu, James Chih-Hsin Yang
Publikováno v:
Journal of Thoracic Oncology. 17:411-422
Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation EGFR tyrosine kinase inhibitor (TKI) with revealed activity against EGFR-sensitizing mutations and EGFR T790M mutation.Patients with locally advanced or metastatic NSCLC who d
Autor:
Michael Duruisseaux, Philippe Brun, Valérie Gounant, Alison M. Schram, Maria E. Arcila, Yonina R. Murciano-Goroff, Miguel Angel Molina, Masaoki Ito, Morihito Okada, Joshua K. Sabari, Denis Moro-Sibilot, Clarisse Dupont, Christina Falcon, Lucia Anna Muscarella, Alexa B. Schrock, Torsten Blum, Alexander Drilon, Marie Wislez, Robert C. Doebele, Haiquan Chen, Eva Brandén, Siraj M. Ali, Fanny Magne, Misako Nagasaka, D. Ross Camidge, Sai-Hong Ignatius Ou, Giulio Rossi, Jin-Yuan Shih, Viola W. Zhu, Jacques Cadranel, Soo-Ryum Yang, Maurice Pérol, Isabelle Monnet, Stephen V. Liu, Rafael Rosell, Ji Youn Han
Publikováno v:
Journal of Clinical Oncology. 39:2791-2802
PURPOSEAlthough NRG1 fusions are oncogenic drivers across multiple tumor types including lung cancers, these are difficult to study because of their rarity. The global eNRGy1 registry was thus established to characterize NRG1 fusion–positive lung c
Autor:
Sai-Hong Ignatius Ou, Yanfei Gao, Viola W. Zhu, Kenneth A. Bauer, Joseph J. Zhao, Nicholas Syn, Shannon S. Zhang, Misako Nagasaka
Publikováno v:
Lung Cancer. 157:147-155
INTRODUCTION Increased thromboembolism (TE) has been reported in ALK+ and ROS1+ non-small cell lung cancer (NSCLC). MATERIALS AND METHODS Odds ratios (OR) and hazard ratios (HR) of TE were calculated from meta-analysis and time-to-event analysis resp
Autor:
Joanne Xiu, Jian Zhang, Viola W. Zhu, Sai-Hong Ignatius Ou, Shannon S. Zhang, Jeffrey Swensen
Publikováno v:
Journal of Thoracic Oncology. 16:e51-e54
Autor:
Viola W. Zhu, Shannon S. Zhang
Publikováno v:
Lung Cancer: Targets and Therapy
The EGFR exon 20 insertion (EGFRex20ins) mutations are the third most common EGFR mutations seen in non-small cell lung cancer (NSCLC). More than 50 variants of EGFRex20ins mutations have been identified with A767_V769dupASV being the most common var
Autor:
Mengzhao Wang, James Chih-Hsin Yang, Paul L. Mitchell, Jian Fang, D. Ross Camidge, Weiqi Nian, Chao-Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu-Chou Su, Tsung-Ying Yang, Viola W. Zhu, Michael Millward, Yun Fan, Wen-Tsung Huang, Ying Cheng, Liyan Jiang, Daniel Brungs, Lyudmila Bazhenova, Chee Khoon Lee, Bo Gao, Yan Xu, Wei-Hsun Hsu, Li Zheng, Pasi A. Jänne
Publikováno v:
Cancer discovery, vol 12, iss 7
Cancer Discov
Cancer Discov
Epidermal growth factor receptor exon 20 insertion mutations (EGFRexon20ins) are detected in approximately 2% of patients with non–small cell lung cancer (NSCLC). Due to a lack of effective therapy, the prognosis of these patients is typically poor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f97c6f089d4647a4230e3bf844f9acf8
https://escholarship.org/uc/item/2sr7d8w2
https://escholarship.org/uc/item/2sr7d8w2
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Steven Zhang, Daniel B. Costa, Gregory J. Riely, Viola W. Zhu, Howard West, Shuanglian Li, Pasi A. Jänne, Alexander I. Spira, Tarek Mekhail, Sylvie Vincent, Joel W. Neal, Jyoti D. Patel, Lyudmila Bazhenova, Shirish M. Gadgeel, Zofia Piotrowska, Veronica Bunn, D. Ross Camidge, Jianchang Lin, S. Jin, Anne S. Tsao, Ryan D. Gentzler, Danny Nguyen
Publikováno v:
Cancer Discovery. 11:1688-1699
Mobocertinib, an oral epidermal growth factor receptor (EGFR) inhibitor targeting EGFR gene mutations, including exon 20 insertions (EGFRex20ins), in non–small cell lung cancer, was evaluated in a phase I/II dose-escalation/expansion trial (Clinica
Autor:
Egbert, F Smit, Christophe, Dooms, Jo, Raskin, Ernest, Nadal, Lye M, Tho, Xiuning, Le, Julien, Mazieres, How, S Hin, Masahire, Morise, Viola, W Zhu, Daniel, Tan, Kristina, H Holmberg, Barbara, Ellers-Lenz, Svenja, Adrian, Sabine, Brutlach, Karl M, Schumacher, Niki, Karachaliou, Yi-Long, Wu
Publikováno v:
Future oncology (London, England). 18(9)
Osimertinib is used to treat a type of lung cancer that has specific changes (mutations) in a gene called